Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2018

Open Access 01-12-2018 | Research article

Varicella in Poland: economic burden in children 1–12 years of age in Poland, 2010–2015

Authors: Jacek Wysocki, Ilona Malecka, Joanna Stryczynska-Kazubska, Emmanouil Rampakakis, Barbara Kuter, Lara J. Wolfson

Published in: BMC Public Health | Issue 1/2018

Login to get access

Abstract

Background

The safety and efficacy of live-attenuated varicella zoster virus (VZV) vaccines in preventing varicella and reducing associated morbidity and mortality in real-world have been previously shown. In Poland, VZV vaccination is only mandatory for certain high-risk individuals. Here, we have conducted an evaluation of the clinical and economic burden of varicella in Poland.

Methods

Multicenter, retrospective chart review of varicella inpatients and outpatients aged 1–12 years with a primary diagnosis between 2010 and 2015. Varicella-related outcomes included the incidence of complications, the proportion of patients reporting healthcare resource utilization (HCRU), and frequency of HCRU. Direct costs were derived from per patient resource use multiplied by unit costs, and indirect costs were calculated as loss of revenue of caregivers reporting work days missed. The overall annual cost of varicella in Poland was estimated based on the calculated direct and indirect costs per case and the estimated number of varicella cases. All costs are presented in 2015 Polish złoty (PLN) / Euros (€).

Results

A total of 150 children with varicella were included, of which 75 were outpatients and 75 were inpatients with a mean (± SD) age of 3.9 (±2.6) and 4.2 (±2.3) years, respectively. Complications were experienced by 14.7% of outpatients and 82.7% of inpatients, of which the most common were skin and soft tissue infections and dehydration. The rate of HCRU was as follows: over-the-counter medications (80.0% outpatients, 81.3% inpatients), prescription medications (80.0% outpatients, 93.3% inpatients), tests/procedures (0.0% outpatients, 69.3% inpatients), and allied health professional consults (0.0% outpatients, 24.0% inpatients). Total (direct and indirect) cost per varicella case was 5013.3 PLN (€ 1198.1) for inpatients and 1027.2 PLN (€ 245.5) for outpatients, resulting in an estimated overall annual (2015) cost of varicella in Poland of 178,198,320 PLN (€ 42,588,385) among children aged 1–15 years.

Conclusions

Significant clinical and economic burden is associated with varicella in Poland. These results may be used to foster discussion related to the implications of implementing routine VZV vaccination in Poland.
Literature
1.
2.
Whitley RJ. Varicella-zoster virus infections. In: Galasso GJ, Whitley RJ, Merigan TC, editors. Antiviral agents and viral diseases of man. New York, New York: Raven Press; 1990.2012. p. 235–63.
3.
Manfredi R, Chiodo F, Titone L, Vierucci A, Catania S, Ghirardini G, et al. Chickenpox complications among immunocompetent hospitalized children in Italy. Acyclovir-chickenpox Italian study group. Pediatr Med Chir. 1997;19(2):99–104.PubMed
4.
Ozdemir H, Candir MO, Karbuz A, Belet N, Tapisiz A, Ciftci E, et al. Chickenpox complications, incidence and financial burden in previously healthy children and those with an underlying disease in Ankara in the pre-vaccination period. Turk J Pediatr. 2011;53(6):614–25.PubMed
5.
Ziebold C, von Kries R, Lang R, Weigl J, Schmitt HJ. Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics. 2001;108(5):E79.PubMed
6.
Bardach A, Cafferata ML, Klein K, Cormick G, Gibbons L, Ruvinsky S. Incidence and use of resources for chickenpox and herpes zoster in Latin America and the Caribbean-a systematic review and meta-analysis. Pediatr Infect Dis J. 2012;31(12):1263–8.PubMedCrossRef
7.
8.
Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis. 2008;197(Suppl 2):S185–S90.PubMedCrossRef
9.
Bollaerts K, Riera-Montes M, Heininger U, Hens N, Souverain A, Verstraeten T, et al. A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. Epidemiol Infect. 2017;145(13):2666–77.PubMedPubMedCentralCrossRef
10.
11.
Narodowy Instytut Zdrowia Publicznego, Pan’stwowy Zakład Higieny, Zakład Epidemiologii; Główny Inspektorat Sanitarny, Departament Zapobiegania oraz Zwalczania Zakaz ˙en ′ i Chorób Zakaz’nych u Ludzi. CHOROBY ZAKAZ ′NE I ZATRUCIA W POLSCE W 2014 ROKU. Available from: wwwold.​pzh.​gov.​pl/​oldpage/​epimeld/​2014/​Ch_​2014.​pdf. Accessed 12 Feb 2016.
12.
Siennicka J, Trzcinska A, Rosinska M, Litwinska B. Seroprevalence of varicella-zoster virus in polish population. Przegl Epidemiol. 2009;63(4):495–9.PubMed
13.
14.
15.
Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics. 1986;78(4 Pt 2):748–56.PubMed
16.
Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr. 1995;127(4):518–25.PubMedCrossRef
17.
Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine. 1991;9(9):643–7.PubMedCrossRef
18.
Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med. 1984;310(22):1409–15.PubMedCrossRef
19.
White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics. 1991;87(5):604–10.PubMed
20.
Baxter R, Ray P, Tran TN, Black S, Shinefield HR, Coplan PM, et al. Long-term effectiveness of varicella vaccine: a 14-year, prospective cohort study. Pediatrics. 2013;131(5):e1389–96.PubMedCrossRef
21.
Nolan T, McIntyre P, Roberton D, Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine. 2002;21(3–4):281–9.PubMedCrossRef
22.
Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, et al. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Eur J Pediatr. 2012;171(3):463–70.PubMedCrossRef
23.
Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006;25(1):12–8.PubMedCrossRef
24.
Lau YL, Vessey SJ, Chan IS, Lee TL, Huang LM, Lee CY, et al. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine. 2002;20(23–24):2942–9.PubMedCrossRef
25.
Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, Andre FE. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. Acta Paediatr Scand. 1991;80(11):1051–7.PubMedCrossRef
26.
Just M, Berger R, Just V. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Dev Biol Stand. 1986;65:85–8.PubMed
27.
Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health. 2015;15:533.PubMedPubMedCentralCrossRef
28.
Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines. 2008;7(6):753–82.PubMedCrossRef
29.
Hirose M, Gilio AE, Ferronato AE, Ragazzi SL. The impact of varicella vaccination on varicella-related hospitalization rates: global data review. Rev Paul Pediatr. 2016;34(3):359–66.PubMedPubMedCentralCrossRef
30.
Trucchi C, Gabutti G, Rota MC, Bella A. Burden of varicella in Italy, 2001-2010: analysis of data from multiple sources and assessment of universal vaccination impact in three pilot regions. J Med Microbiol. 2015;64(11):1387–94.PubMedCrossRef
31.
32.
Weile LK, Kahn JG, Marseille E, Jensen DM, Damm P, Lohse N. Global cost-effectiveness of GDM screening and management: current knowledge and future needs. Best Pract Res Clin Obstet Gynaecol. 2015;29(2):206–24.PubMedCrossRef
33.
34.
35.
Fornaro P, Gandini F, Marin M, Pedrazzi C, Piccoli P, Tognetti D, et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Italian sentinel group on pediatric infectious diseases. Pediatr Infect Dis J. 1999;18(5):414–9.PubMedCrossRef
36.
Iseli A, Aebi C, Banz K, Brunner M, Schmutz AM, Heininger U. Prospective surveillance of varicella-zoster virus infections in an out-patient setting in Switzerland. Hum Vaccin. 2009;5(12):843–6.PubMedCrossRef
37.
Wagenpfeil S, Neiss A, Banz K, Wutzler P. Empirical data on the varicella situation in Germany for vaccination decisions. Clin Microbiol Infect. 2004;10(5):425–30.PubMedCrossRef
38.
Blumental S, Sabbe M, Lepage P, Belgian Group for V. Varicella paediatric hospitalisations in Belgium: a 1-year national survey. Arch Dis Child. 2016;101(1):16–22.PubMedCrossRef
39.
Liese JG, Grote V, Rosenfeld E, Fischer R, Belohradsky BH, Kries R, et al. The burden of varicella complications before the introduction of routine varicella vaccination in Germany. Pediatr Infect Dis J. 2008;27(2):119–24.PubMedCrossRef
40.
Turel O, Bakir M, Gonen I, Hatipoglu N, Aydogmus C, Hosaf E, et al. Children hospitalized for varicella: complications and cost burden. ViHRI. 2013;2:226–30.
41.
Diez-Domingo J, Aristegui J, Calbo F, Gonzalez-Hachero J, Moraga F, Pena Guitian J, et al. Epidemiology and economic impact of varicella in immunocompetent children in Spain. A nation-wide study. Vaccine. 2003;21(23):3236–9.PubMedCrossRef
42.
Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med Microbiol Immunol. 2002;191(2):89–96.PubMedCrossRef
43.
Arama V, Rafila A, Streinu-Cercel A, Pistol A, Bacruban R, Sandu R, et al. Varicella in Romania: epidemiological trends, 1986-2004. Euro Surveill. 2005;10(8):E0508116.
44.
Bramley JC, Jones IG. Epidemiology of chickenpox in Scotland: 1981 to 1998. Commun Dis Public Health. 2000;3(4):282–7.PubMed
45.
Dubos F, Grandbastien B, Hue V, Hospital Network for Evaluating Management of Common Childhood D, Martinot A. Epidemiology of hospital admissions for paediatric varicella infections: a one-year prospective survey in the pre-vaccine era. Epidemiol Infect. 2007;135(1):131–8.PubMedCrossRef
46.
Theodoridou M, Laina I, Hadjichristodoulou C, Syriopoulou V. Varicella-related complications and hospitalisations in a tertiary pediatric medical center before vaccine introduction. Eur J Pediatr. 2006;165(4):273–4.PubMedCrossRef
47.
Grote V, von Kries R, Springer W, Hammersen G, Kreth HW, Liese J. Varicella-related deaths in children and adolescents--Germany 2003-2004. Acta Paediatr. 2008;97(2):187–92.PubMedCrossRef
48.
Grimprel E, Levy C, de La Rocque F, Cohen R, Soubeyrand B, Caulin E, et al. Paediatric varicella hospitalisations in France: a nationwide survey. Clin Microbiol Infect. 2007;13(5):546–9.PubMedCrossRef
49.
Gowin E, Wysocki J, Michalak M. Don't forget how severe varicella can be--complications of varicella in children in a defined polish population. Int J Infect Dis. 2013;17(7):e485–9.PubMedCrossRef
50.
Mallet E, Maitre M, Delalande-Dutilleul L, Marguet C, Mouterde O. Evaluation of varicella complications through a retrospective hospital survey in a paediatric center over 16 years in France. Arch Pediatr. 2004;11(9):1145–51.PubMedCrossRef
51.
Marchetto S, de Benedictis FM, de Martino M, Versace A, Chiappini E, Bertaine C, et al. Epidemiology of hospital admissions for chickenpox in children: an Italian multicentre study in the pre-vaccine era. Acta Paediatr. 2007;96(10):1490–3.PubMedCrossRef
52.
Bonhoeffer J, Baer G, Muehleisen B, Aebi C, Nadal D, Schaad UB, et al. Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr. 2005;164(6):366–70.PubMedCrossRef
53.
Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol. 2003;70(Suppl 1):S9–14.PubMedCrossRef
54.
Glogowski C, Gierczynski J, Splawinski J. Pin 42: cost of varicella in Poland. Value Health. 2003;6(3):267.CrossRef
55.
56.
Meszner Z, Molnar Z, Rampakakis E, Yang HK, Kuter BJ, Wolfson LJ. Economic burden of varicella in children 1-12 years of age in Hungary, 2011-2015. BMC Infect Dis. 2017;17(1):495.PubMedPubMedCentralCrossRef
57.
Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain: results from a dynamic model. Vaccine. 2006;24(47–48):6980–9.PubMedCrossRef
58.
Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health. 2005;8(3):209–22.PubMedCrossRef
Metadata
Title
Varicella in Poland: economic burden in children 1–12 years of age in Poland, 2010–2015
Authors
Jacek Wysocki
Ilona Malecka
Joanna Stryczynska-Kazubska
Emmanouil Rampakakis
Barbara Kuter
Lara J. Wolfson
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2018
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-018-5298-8

Other articles of this Issue 1/2018

BMC Public Health 1/2018 Go to the issue

Research article

SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): a randomised controlled trial

Research article

Validating Fitbit Zip for monitoring physical activity of children in school: a cross-sectional study

Research article

Associations between ideational variables and bed net use in Madagascar, Mali, and Nigeria

Research article

AIDS incidence trends at presentation and during follow-up among HIV-at-risk populations: a 15-year nationwide cohort study in Taiwan

Research article

The impact of a private sector living wage intervention on consumption and cardiovascular disease risk factors in a middle income country

Research article

Current high prevalences of Strongyloides stercoralis and Opisthorchis viverrini infections in rural communities in northeast Thailand and associated risk factors